Search

Search Results for "tyrosine-kinase inhibitors"

AAO 2021 Late Breakers: DAVIO and NORSE-2

TKIs and the Future of Care thumbnail

TKIs and the Future of Care

Maria Berrocal, MD and Dilsher Dhoot, MD

A TKI Update for Wet AMD thumbnail

A TKI Update for Wet AMD

Carl D. Regillo, MD and R.V. Paul Chan, MD, MSc, MBA, FACS

TKIs: How Do They Work? thumbnail

TKIs: How Do They Work?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

Next-Gen Therapies for AMD and DME thumbnail

Next-Gen Therapies for AMD and DME

Nicole Eter, MD

What's New in Wet AMD: Phase 3 Updates thumbnail

What's New in Wet AMD: Phase 3 Updates

Jennifer Lim, MD

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))? thumbnail

What is EYP-1901 (DURAVYU™, (vorolanib intravitreal insert))?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME? thumbnail

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Treating DR with Axitinib thumbnail

Treating DR with Axitinib

Neal S. Shah, MD

Patient Selection for EYP-1901 thumbnail

Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Reinjection Criteria thumbnail

Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Wet AMD and DME Therapy in Development thumbnail

Wet AMD and DME Therapy in Development

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD? thumbnail

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901? thumbnail

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials? thumbnail

Why Do Real-World Wet AMD Outcomes Differ From Those Seen in Clinical Trials?

Sophie Bakri, MD; Durga S. Borkar, MD, MMCi; and Jayanth Sridhar, MD

ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the Pipeline

David Miller, MD; and Robert Wang, MD

AAO 2021 Late Breakers: DAVIO and NORSE-2

David Boyer, MD; and Firas Rahhal, MD

View More